Global Thyroid Eye Disease (TED) Market Report 2021: Horizon Therapeutics has the Highest Amount of Ongoing Clinical Trials and Highest Overall Number of Clinical Trials
June 18, 2021 05:38 ET
|
Research and Markets
Dublin, June 18, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Thyroid Eye Disease (TED)" report has been added to ResearchAndMarkets.com's offering. Thyroid eye disease (TED), also called Graves'...
Global Glaucoma Market Pipeline Spotlight Report 2021 - Novartis Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by AbbVie
June 10, 2021 06:43 ET
|
Research and Markets
Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Glaucoma" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Glaucoma market,...
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021
June 09, 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
May 28, 2021 16:30 ET
|
Novartis Pharma AG
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus...
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference
May 24, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops
May 17, 2021 09:00 ET
|
Harrow Health, Inc.
NASHVILLE, Tenn., May 17, 2021 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly owned subsidiary of...
Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
May 14, 2021 07:30 ET
|
Biogen Inc.
While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual...
Eyenuk Reports Strong 2021 Business Growth
May 12, 2021 11:00 ET
|
Eyenuk, Inc.
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments
May 12, 2021 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD
May 12, 2021 07:00 ET
|
Graybug Vision, Inc.
GB-102 1mg has shown competitive durability and anatomical control versus afliberceptTrend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patientsDeveloping...